<DrugInformationSummary id="CDR0000791271"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about axicabtagene ciloleucel
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/axicabtageneciloleucel">Axicabtagene Ciloleucel</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000768723">axicabtagene ciloleucel</TerminologyLink><GlossaryLink ref="CDR0000791266">axicabtagene ciloleucel</GlossaryLink><USBrandNames><USBrandName>Yescarta</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>AK-see-KAB-tuh-jeen sy-loh-LOO-sel</TermPronunciation><MediaLink ref="CDR0000792224" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000792225" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b70606e-b99c-4272-a0f1-b5523cce0c59&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Axicabtagene Ciloleucel</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b70606e-b99c-4272-a0f1-b5523cce0c59&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Axicabtagene ciloleucel
         is approved to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444967" dictionary="Cancer.gov" audience="Patient">B-cell non-Hodgkin lymphoma</GlossaryTermRef></Strong> (NHL), including the following types:<ItemizedList Style="bullet" id="_9"><ListItem><GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">diffuse large B-cell lymphoma</GlossaryTermRef> (DLBCL)</ListItem><ListItem>DLBCL in patients who had <GlossaryTermRef href="CDR0000428287" dictionary="Cancer.gov" audience="Patient">follicular lymphoma</GlossaryTermRef></ListItem><ListItem>follicular lymphoma¹</ListItem><ListItem><GlossaryTermRef href="CDR0000777025" dictionary="Cancer.gov" audience="Patient">primary mediastinal large B-cell lymphoma</GlossaryTermRef></ListItem><ListItem><GlossaryTermRef href="CDR0000045710" dictionary="Cancer.gov" audience="Patient">high-grade</GlossaryTermRef> B-cell lymphoma<Para id="_10">It is used in adults whose cancer came back or did not get better after at least two other <GlossaryTermRef href="CDR0000045922" dictionary="Cancer.gov" audience="Patient">systemic therapies</GlossaryTermRef>.</Para></ListItem></ItemizedList></ListItem><ListItem><Strong>DLBCL</Strong> that did not respond to <GlossaryTermRef href="CDR0000346494" dictionary="Cancer.gov" audience="Patient">first-line</GlossaryTermRef> <GlossaryTermRef href="CDR0000270867" dictionary="Cancer.gov" audience="Patient">chemoimmunotherapy</GlossaryTermRef> or that relapsed within 12 months of first-line chemoimmunotherapy</ListItem>
   
   </ItemizedList>
  <Para id="_6">Axicabtagene ciloleucel is only available as part of a special program called Yescarta REMS (<ExternalRef xref="https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&amp;REMS=375">Risk Evaluation and Mitigation Strategies</ExternalRef>).</Para><Para id="_8">¹This use is approved under FDA’s <ExternalRef xref="https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm">Accelerated Approval Program</ExternalRef>. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that axicabtagene ciloleucel provides a clinical benefit in these patients.</Para><Para id="_7">Axicabtagene ciloleucel
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Axicabtagene Ciloleucel</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/768723">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.63">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a618003.html">Axicabtagene Ciloleucel</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.64"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.65">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/car-t-cell-therapy-second-cancers">Understanding the Risk of Second Cancers After CAR T-Cell Therapy</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/large-b-cell-lymphoma-axi-cel-zuma-7-trial">Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy">T-cell Transfer Therapy</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/research/car-t-cells">CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C120309">Find Clinical Trials for Axicabtagene Ciloleucel</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2017-10-20</DateFirstPublished><DateLastModified>2025-01-02</DateLastModified></DrugInformationSummary>
